drugset / Trial / NCT01638208
Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D
RandomizedSingle-groupOpen-labelTreatment
Summary
Aim To compare changes in gut microbiota of IBS patients and healthy controls using next generation sequencing method like Illumina sequencing based on 16S rDNA profiling. The major objectives of the study are: To characterize type of bacterial species and compare diversity of the host's gut microbiota in 20 Irritable bowel syndrome (IBS) patients with 16 healthy controls (HCs) using high through put culture-independent method like Illumina sequencing. To study modulation of gut microbiota profile after treatment with probiotics (VSL #3) for 8 weeks. To study the improvement of symptoms after modulation of gut microbiota with probiotics (VSL #3) for more than 8 weeks.
Timeline
- Start
- 2012-08
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VSL#3 | Other / unclassified | 112.5 unknown | — |